Pay Attention to EXEL# Stock
c*r
1 楼
EXEL:
The company has the best line up of MAPK pathway inhibitors
Its pipeline is very complementary to ROCHE's, is a speculated target for
ROCHE.
Its MEK inhibitor cobimetinib is the best in class, and has shown good
results in combination with ROCHE's RAF inhibitor and PI3K inhibitor
Its market cap is only 700 million, a bargain for a biotech with a drug
already approved to market
etc etc.
The company has the best line up of MAPK pathway inhibitors
Its pipeline is very complementary to ROCHE's, is a speculated target for
ROCHE.
Its MEK inhibitor cobimetinib is the best in class, and has shown good
results in combination with ROCHE's RAF inhibitor and PI3K inhibitor
Its market cap is only 700 million, a bargain for a biotech with a drug
already approved to market
etc etc.